Avion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patients
Haryana Blog/10199540
Trending...
- TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
- Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
- Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
MELBOURNE, Australia - HaryanaBlog -- Avion Medical Skin Centres (AMSC) have entered into an agreement with OncoBeta® GmbH to treat non-melanoma skin cancer (NMSC) patients in Australia, with the new, non-invasive [1] [2] Rhenium-SCT®. The first AMSC location will open in Melbourne Victoria, to patients in Q3 2022. Treatments will be provided at a brand-new world-class facility at the Melbourne Theranostics Innovation Centre (MTIC) in North Melbourne, which provides unparalleled access to a combination of nuclear medicine technologies, therapeutics and innovative research.
AMSC is partnering with Munich-based medical device and radiochemical company, OncoBeta, who are pioneering epidermal radioisotope therapy and successfully launched Rhenium-SCT – which is set to change the way people think about NMSC treatment. Where traditional treatment methods typically involve surgery, which may have a risk of scarring or loss of function, treatment with Rhenium-SCT employs a non-invasive [1] [2] superficial application of a paste containing ß-emitting particles directly to the lesion, which eliminate cancer cells without the need for surgery. Treatment with Rhenium-SCT is painless [1] [2] and only requires a single session [1] [2] [3] [4] [5] in most cases.
Dr. Sam Vohra, founder of AMSC, says, "We are very proud to be opening this new treatment centre in the heart of Melbourne's oncology precinct and to offer this ground-breaking treatment to NMSC patients in Australia. The clinical evidence has already proven that Rhenium-SCT is an effective alternative to traditional invasive options and can significantly improve patient outcomes and quality of life."
More on Haryana Blog
Professor Rod Hicks, a pioneer of therapeutic nuclear medicine and founder of MTIC notes, "The use of externally applied radioisotopes to successfully cure skin cancers goes back to the start of the last century and the discovery of radium by Marie Curie. We have known for over a hundred years that this approach works but the Oncobeta approach brings this treatment into the 21st century with high precision in the application of radiation only to the skin cancer, sparing normal skin and without the disfiguring surgery sometimes otherwise required."
Shannon D. Brown III, CEO and Managing Director at OncoBeta, recently visited Australia, and says "We are focused on providing Rhenium-SCT in countries with the highest need, to provide as many patients as possible with beneficial clinical outcomes and positive effect on patients' quality of life. We are extremely excited for this partnership with Avion Medical Skin Centres and continuing to support physicians involved in the diagnosis and treatment of NMSCs."
Australia has the highest incidence of NMSC in the world, and diagnosis rates are continuing to rise each year [6] [7]. NMSCs are most common in areas that are exposed to the sun, including the face, head and neck/shoulders [8]. Avion Medical Skin Centres offers NMSC sufferers a highly effective [2] treatment option that removes the fear and hesitation some patients may feel around aesthetic outcomes or loss of function.
For more information about Avion Medical Skin Centres please visit www.avionmedicalskin.com.au or for more information about OncoBeta and Rhenium-SCT please visit: www.oncobeta.com.
More on Haryana Blog
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of Avion Medical's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Avion Medical's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Avion Medical undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
For media enquiries, please contact via email: press@showoffgroup.com
References
AMSC is partnering with Munich-based medical device and radiochemical company, OncoBeta, who are pioneering epidermal radioisotope therapy and successfully launched Rhenium-SCT – which is set to change the way people think about NMSC treatment. Where traditional treatment methods typically involve surgery, which may have a risk of scarring or loss of function, treatment with Rhenium-SCT employs a non-invasive [1] [2] superficial application of a paste containing ß-emitting particles directly to the lesion, which eliminate cancer cells without the need for surgery. Treatment with Rhenium-SCT is painless [1] [2] and only requires a single session [1] [2] [3] [4] [5] in most cases.
Dr. Sam Vohra, founder of AMSC, says, "We are very proud to be opening this new treatment centre in the heart of Melbourne's oncology precinct and to offer this ground-breaking treatment to NMSC patients in Australia. The clinical evidence has already proven that Rhenium-SCT is an effective alternative to traditional invasive options and can significantly improve patient outcomes and quality of life."
More on Haryana Blog
- LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
- Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
- Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
- BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
- Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
Professor Rod Hicks, a pioneer of therapeutic nuclear medicine and founder of MTIC notes, "The use of externally applied radioisotopes to successfully cure skin cancers goes back to the start of the last century and the discovery of radium by Marie Curie. We have known for over a hundred years that this approach works but the Oncobeta approach brings this treatment into the 21st century with high precision in the application of radiation only to the skin cancer, sparing normal skin and without the disfiguring surgery sometimes otherwise required."
Shannon D. Brown III, CEO and Managing Director at OncoBeta, recently visited Australia, and says "We are focused on providing Rhenium-SCT in countries with the highest need, to provide as many patients as possible with beneficial clinical outcomes and positive effect on patients' quality of life. We are extremely excited for this partnership with Avion Medical Skin Centres and continuing to support physicians involved in the diagnosis and treatment of NMSCs."
Australia has the highest incidence of NMSC in the world, and diagnosis rates are continuing to rise each year [6] [7]. NMSCs are most common in areas that are exposed to the sun, including the face, head and neck/shoulders [8]. Avion Medical Skin Centres offers NMSC sufferers a highly effective [2] treatment option that removes the fear and hesitation some patients may feel around aesthetic outcomes or loss of function.
For more information about Avion Medical Skin Centres please visit www.avionmedicalskin.com.au or for more information about OncoBeta and Rhenium-SCT please visit: www.oncobeta.com.
More on Haryana Blog
- Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
- Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
- UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
- Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
- Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of Avion Medical's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Avion Medical's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Avion Medical undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
For media enquiries, please contact via email: press@showoffgroup.com
References
- Sedda AF, et al. Clin Exper Dermatol. 2008;33:745–749.
- Cipriani C, et al. J Dermatol Treat. 2020; DOI: 10.1080/09546634.2020.1793890.
- Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021;48:1511–1521.
- Cipriani C, et al. International Journal of Nuclear Medicine. 2017; July: 114–112.
- Cipriani C, et al. Epidermal Radionuclide Therapy - Springer, 2014.
- Lomas A, Leonardi-Bee J, Bath-Hextall F. 2012 May;166(5):1069-80. doi: 10.1111/j.1365-2133.2012.10830.x.
- Diepgen TL & Mahler VM. Br J Dermatol. 2002;146 (Suppl 61):1–6.
- Cancer Council Australia. https://www.cancer.org.au/cancer-information/types-of-cancer/non-melanoma-skin-cancer (accessed June 2022).
Source: Avion Medical Skin Centres
0 Comments
Latest on Haryana Blog
- Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
- Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
- ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
- Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
- Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
- The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
- New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
- Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
- Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
- Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
- Andrew Balzano Releases One of My Life's Passions: Classics and Mysteries, a Fan's Guide to Great Mysteries Worth Rewatching
- The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
- Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category
- HIRO Ostomy Belt Launch by Richard O'Hamill
- New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
- Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
- The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
- Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
